STEVEN GILLIS
CIK 1229592 · Ex. Chair. & President · last filed 2026-07-06
STEVEN GILLIS is an Ex. Chair. & President who has filed 60 SEC Form 4 insider transactions across 10 companies since 2007. The most recent filing, for BOLD, was dated Jul 6, 2026. Across all open-market trades the lifetime net is +$134.5M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $142.3M across reported positions. 45 SEC filings were submitted jointly with KEITH CRANDELL.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$142.26M
10
60
$134.54M
Filer Profile
SUITE 1025
CHICAGO, IL 60631
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BOLD | 10%+ Owner | 828,570 | $2.66 | $2.20M | -$199.2K | 1 | 2026-07-06 |
| TAK | Director | 10,400 | $18.86 | $196.1K | $0 | 1 | 2026-07-06 |
| SPTX | 10%+ Owner | 6,294,951 | $21.52 | $135.47M | $138.60M | 1 | 2026-05-04 |
| Metsera, Inc. (MTSR) Delisted | Director | 0 | $70.50 | $0 | $0 | 1 | 2025-11-14 |
| VBI Vaccines Inc/BC (VBIV) Delisted | Director | 1,046,106 | $0.07 | $68.3K | $1.92M | 15 | 2023-07-28 |
| FIXX | Director | 337,150 | $13.02 | $4.39M | $0 | 7 | 2023-06-15 |
| Codiak BioSciences, Inc. (CDAK) Delisted | Director | 7,512,653 | $0.06 | $428.2K | $3.52M | 7 | 2023-02-21 |
| PULM | Director | — | $1.61 | — | $0 | 8 | 2020-09-01 |
| bluebird bio, Inc. (BLUE) Delisted | Director | 5,466 | $4.97 | $27.2K | -$9.31M | 10 | 2015-07-30 |
| Trubion Pharmaceuticals, Inc (TRBN) Delisted | Ex. Chair. & President | 0 | — | — | $0 | 6 | 2010-10-28 |
Recent Filings
60 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-06 | BOLD | Mixed | — | -$116.8K | EDGAR |
| 2026-07-06 | TAK | Mixed | +3,800 | $0 | EDGAR |
| 2026-05-04 | SPTX | Mixed | +44,064,657 | $138.60M | EDGAR |
| 2025-11-14 | Metsera, Inc. (MTSR) Delisted | Disp (D) | −241,351,272 | $0 | EDGAR |
| 2023-07-28 | VBI Vaccines Inc/BC (VBIV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-07-18 | VBI Vaccines Inc/BC (VBIV) Delisted | Buy (P) | +609,090 | $1.00M | EDGAR |
| 2023-06-15 | FIXX | Grant (A) | — | $0 | EDGAR |
| 2023-02-21 | Codiak BioSciences, Inc. (CDAK) Delisted | Exer (M) | +8,750 | $0 | EDGAR |
| 2023-01-30 | VBI Vaccines Inc/BC (VBIV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-09-15 | Codiak BioSciences, Inc. (CDAK) Delisted | Buy (P) | +5,000,000 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.